Press Releases VALBIOTIS

Equities

ALVAL

FR0013254851

Market Closed - Euronext Paris Other stock markets 11:35:28 2024-06-07 am EDT			5-day change	1st Jan Change
2 ^EUR	-5.21%		-48.59%	-60.00%

Jun. 04	Valbiotis Terminates Licensing, Supply Deal With Nestlé Unit	MT
Jun. 04	Valbiotis: share price plummets, Nestlé agreement terminated	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Valbiotis : reaches an agreement to terminate its licensing and supply agreement with Nestlé Health Science	Jun. 06	PU
Valbiotis reaches an agreement to terminate its licensing and supply agreement with Nestlé Health Science	Jun. 04	EQ
Valbiotis launches its e-commerce site for the marketing of Valbiotis®PRO Cholestérol	May. 22	EQ
Valbiotis publishes its annual accounts 2023	Apr. 26	EQ
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May	Apr. 03	EQ
Valbiotis presents its 2024 financial communication calendar	Jan. 29	EQ
Valbiotis sets out its commercial and clinical roadmap for 2024	Jan. 16	EQ
Valbiotis announces the success of its €15 M capital increase	Dec. 22	EQ
Valbiotis announces the launch of a capital increase	Dec. 11	EQ
Valbiotis announces the availability of an amendment to the Universal Registration Document	Dec. 11	EQ
Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status	Dec. 11	EQ
VALBIOTIS SA:	Dec. 04	EQ
Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes	Nov. 07	EQ
VALBIOTIS : Rapport financier semestriel 2023	23-10-15	PU
VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes	23-10-02	EQ
Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap	23-09-28	EQ
Valbiotis presents the full results of the Phase II/III REVERSE-IT study, impressive efficacy of TOTUM 63 against prediabetes and the early stages of type 2 Diabetes, a first for a non-drug active substance	23-09-12	AQ
VALBIOTIS SA: Valbiotis presents the full results of the Phase II/III REVERSE-IT study: impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes	23-09-11	EQ
Valbiotis announces its roadmap and strategic priorities on the eve of key milestones for its portfolio of innovative active substances	23-07-12	EQ
Valbiotis announces the appointment of Charlotte JEZEQUEL as Director of Human Relations and Executive Committee member	23-07-03	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases VALBIOTIS

Equities

ALVAL

FR0013254851

Press Releases

Filters